Free Trial
NASDAQ:PRME

Prime Medicine Q2 2026 Earnings Results & Report

Prime Medicine logo
$4.34 +0.46 (+11.70%)
As of 12:50 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Prime Medicine met analyst earnings expectations and missed on revenue in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.24 versus the -$0.24 consensus estimate, while revenue of $1.15 million fell short of the $4.40 million estimate by $3.25 million.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Prime Medicine EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.24
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Prime Medicine Revenue Results

Actual Revenue
$1.15 million
Expected Revenue
$4.40 million
Beat/Miss
Missed by -$3.25 million
YoY Revenue Growth
N/A

Prime Medicine Q2 2026 Earnings FAQ

Prime Medicine (NASDAQ:PRME) reported earnings of -$0.24 per share for Q2 2026, matching the consensus estimate of -$0.24. The report was announced on Thursday, August 6, 2026.

Prime Medicine reported revenue of $1.15 million for Q2 2026, against a consensus estimate of $4.40 million.

Prime Medicine Earnings Headlines

Prime Medicine Q3 Loss Narrows, Revenue Rises
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Prime Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prime Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prime Medicine and other key companies, straight to your email.

About Prime Medicine

Prime Medicine (NASDAQ:PRME) is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions.

The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies.

Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts. Its technology is rooted in research by geneticist David Liu and colleagues, who helped develop prime editing.

View Prime Medicine Profile